Please assess the completion status of the following clinical trial:

Trial Title: Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects 18 years of age or older~* Female subjects 18 years of age or older of non-child bearing potential defined by a serum follicle stimulating hormone (FSH) level ≥ 25.8 mIU/ml or by a confirmed clinical history of sterility (e.g. hysterectomy)~* Renal transplantation performed two years or more before inclusion~* Stable renal transplant function as determined by physician~* Actinic keratosis, one or multiple, of the trunk and/or extremities, non-hypertrophic non-hyperkeratotic based on clinical judgment within an area of 100 cm2 total (several areas adding up to 100 cm2 permissible)~* Signed Informed Consent after oral and written explanation of the study protocol~Exclusion Criteria:~* contraindications on ethical grounds such as inability to give informed consent~* women of child-bearing potential, women who are pregnant or breast feeding~* other clinically significant concomitant disease (e.g. hepatic dysfunction, cardiovascular disease, etc) at the investigator's discretion~* known or suspected non-compliance, drug or alcohol abuse~* enrolment into a clinical trial within last 4 weeks~* prior treatment with ingenol mebutate gel~* prior local/topical treatments in the treatment area within 2 weeks of trial entry:~  * Dermabrasion, chemical peeling, laser treatment, cryotherapy or surgery~ * Imiquimod, diclofenac, 5-Fluorouracil (5-FU), topical corticosteroids, topical retinoids, treatment with ultraviolet B (UVB) or photodynamic treatment (PDT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ingenol mebutate 500 ucg (Type: EXPERIMENTAL): active arm

Based on this trial design, predict the completion outcome and termination type (if applicable).